Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-04-04
Disclosure Type: Single Sales/Supply Contract (Amendment)
💡 3-Second Summary
Samsung Biologics has substantially increased its biopharmaceutical contract manufacturing organization (CMO) contract with a Merck subsidiary (Merck Sharp & Dohme (Switzerland) GmbH) from approximately KRW 92.8 billion to KRW 247.3 billion, an upward revision driven by the successful commercialization of the client’s product.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Counterparty: Merck Sharp & Dohme (Switzerland) GmbH
- Contract Type: Biopharmaceutical Contract Manufacturing Organization (CMO) Contract
- Contract Amount (Amended):
- (Before) KRW 92,769,116,464 (USD 70,579,060)
- (After) KRW 247,342,556,464 (USD 188,179,060)
- Net Increase: Increased by USD 117,600,000 (Approx. KRW 154.6B).
- Exchange Rate: Calculated by applying the initial exchange rate of 1,314.40 KRW/USD from the original disclosure date (March 12, 2024).
- Proportion to Annual Revenue (Amended):
- (Before) 3.09% → (After) 8.24%
- The baseline annual revenue (KRW 3,001,295,197,683) is based on the company’s 2022 consolidated financial statements from the initial filing.
- Contract Period: March 1, 2024 – December 31, 2032 (Subject to change upon mutual agreement).
- Reason for Amendment: Change in contract amount due to the successful commercialization of the client’s product.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Impact on Fundamental Changes: This disclosure outlines a material upward revision of a contract total by more than KRW 154.6 billion. By increasing the cumulative contract value with the Merck subsidiary to KRW 247.3 billion (8.24% of baseline revenue) through late 2032, this update expands the long-term revenue pipeline, which may generate a positive potential impact on financial metrics over the contract duration.
- Risks and Red Flags for Investors: The regulatory filing explicitly states the reason for the adjustment as the “successful commercialization of the client’s product.” However, specific operational details such as quarterly production allocations or delivery terms following the commercialization are not provided, meaning investors should avoid forming ungrounded conclusions. Additionally, because the monetary figures remain anchored to the historical exchange rate of 1,314.40 KRW/USD from March 2024, actual reported revenue could vary depending on spot exchange rates during active billing periods. Furthermore, as the contract end date is subject to change based on mutual agreement, the timeline for quarterly revenue recognition may remain fluid.
📝 Editor’s Comment (by K-STOCK Editor)
Less than a month after the initial filing, a large-scale upward amendment in the hundreds of billions of won has been finalized, pushing the contract’s proportion relative to baseline revenue up to 8.24%. The stated reason for the amendment—the successful commercialization of the global Big Pharma client’s product—presents a clear operational linkage. As the client’s commercialization reaches fruition, the cumulative size of this long-term deal with its manufacturing partner has expanded significantly. Market participants may focus heavily on this expanded baseline, though investors will want to observe carefully how this adjustment translates into long-term potential impacts on actual financial performance.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
